Quality-of-life considerations in treatment of unresectable, recurrent head and neck cancer

References

• Specenier P, Vermorken J. Recurrent head and neck cancer: current treatment and future prospects. Expert Rev. Anticancer Ther.8(3), 375–391 (2008).
   PubMed Web of Science ®Google Scholar
• Hoffman HT, Porter K, Karnell LH et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope116(9 Pt 2 Suppl. 111), 1–13 (2006).
   PubMed Web of Science ®Google Scholar
• Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int. J. Cancer114(5), 806–816 (2005).
   PubMed Web of Science ®Google Scholar
• Coatesworth AP, Tsikoudas A, MacLennan K. The cause of death in patients with head and neck squamous cell carcinoma. J. Laryngol. Otol.116(4), 269–271 (2002).
   PubMed Web of Science ®Google Scholar
• Leon X, Hitt R, Constenla M et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin. Oncol. (R. Coll. Radiol.)17(6), 418–424 (2005).
   PubMed Web of Science ®Google Scholar
• Jones AS. The untreated patient with squamous carcinoma of the head and neck. Am. J. Clin. Oncol.18(4), 363–368 (1995).
   PubMedGoogle Scholar
• Kao J, Garofalo MC, Milano MT, Chmura SJ, Citron JR, Haraf DJ. Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review. Cancer Treat. Rev.29(1), 21–30 (2003).
   PubMed Web of Science ®Google Scholar
• Wibault P, Bensmaine MA, de Forni M et al. Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a Phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. J. Clin. Oncol.14(4), 1192–1200 (1996).
   PubMedGoogle Scholar
• Ohizumi Y, Tamai Y, Imamiya S, Akiba T. Complications following re-irradiation for head and neck cancer. Am. J. Otolaryngol.23(4), 215–221 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA273(1), 59–65 (1995).
   PubMed Web of Science ®Google Scholar
• Tschiesner U, Rogers SN, Harreus U, Berghaus A, Cieza A. Content comparison of quality of life questionnaires used in head and neck cancer based on the international classification of functioning, disability and health: a systematic review. Eur. Arch. Otorhinolaryngol.265(6), 627–637 (2008).
   PubMed Web of Science ®Google Scholar
• Ringash J, Bezjak A. A structured review of quality of life instruments for head and neck cancer patients. Head Neck23(3), 201–213 (2001).
   PubMed Web of Science ®Google Scholar
• Revicki D, Kaplan R. Relationship between psychometric and utility-based approaches to the measurement of health related quality of life. Qual. Life Res.2(6), 477–487 (1993).
   PubMed Web of Science ®Google Scholar
• Jalukar V, Funk GF, Christensen AJ, Karnell LH, Moran PJ. Health states following head and neck cancer treatment: patient, health-care professional, and public perspectives. Head Neck20(7), 600–608 (1998).
   PubMed Web of Science ®Google Scholar
• Bjordal K, de Graeff A, Fayers PM et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life group. Eur. J. Cancer36(14), 1796–1807 (2000).
   PubMed Web of Science ®Google Scholar
• Guntinas-Lichius O, Rühlow S, Veelken F, Klussmann JP. Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. J. Cancer Res. Clin. Oncol.135, 901–908 (2009).
   PubMedGoogle Scholar
• Stewart JS, Cohen EE, Licitra L et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol.27(11), 1864–1871 (2009).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med.359(11), 1116–1127 (2008).
   PubMed Web of Science ®Google Scholar
• Goldstein DP, Hynds Karnell L, Christensen AJ, Funk GF. Health-related quality of life profiles based on survivorship status for head and neck cancer patients. Head Neck29(3), 221–229 (2007).
   PubMedGoogle Scholar
• Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin. Proc.83(4), 489–501 (2008).
   PubMed Web of Science ®Google Scholar
• Rivera F, Garcia-Castano A, Vega N, Vega-Villegas ME, Gutierrez-Sanz L. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev. Anticancer Ther.9(10), 1421–1428 (2009).
   PubMed Web of Science ®Google Scholar
• Mowry SE, Ho A, LoTempio MM, Sadeghi A, Blackwell KE, Wang MB. Quality of life in advanced oropharyngeal carcinoma after chemoradiation versus surgery and radiation. Laryngoscope116(9), 1589–1593 (2006).
   PubMed Web of Science ®Google Scholar
• Corry J, Peters LJ, Costa ID et al. The ‘QUAD SHOT’ – a Phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother. Oncol.77(2), 137–142 (2005).
   PubMedGoogle Scholar
• Porceddu SV, Rosser B, Burmeister BH et al. Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment – ‘Hypo Trial’. Radiother. Oncol.85(3), 456–462 (2007).
   PubMedGoogle Scholar
• Al-Mamgani A, Tans L, Van Rooij PH, Noever I, Baatenburg de Jong RJ, Levendag PC. Hypofractionated radiotherapy denoted as the ‘Christie scheme’: an effective means of palliating patients with head and neck cancers not suitable for curative treatment. Acta Oncol.48(4), 562–570 (2009).
   PubMed Web of Science ®Google Scholar
• Paleri V, Kelly C. Re-irradiation with concurrent chemotherapy in recurrent head and neck cancer: a decision analysis model based on a systematic review. Clin. Otolaryngol.33, 331–337 (2008).
   PubMedGoogle Scholar
• Goldstein D, Karnell L, Yao M, Chamberlin G, Nguyen T, Funk G. Outcomes following reirradiation of patients with head and neck cancer. Head Neck30(6), 765–770 (2008).
   PubMed Web of Science ®Google Scholar
• Kasperts N, Slotman B, Leemans CR, Langendijk JA. A review on re-irradiation for recurrent and second primary head and neck cancer. Oral Oncol.41(3), 225–243 (2005).
   PubMedGoogle Scholar
• Creak AL, Harrington K, Nutting C. Treatment of recurrent head and neck cancer: re-irradiation or chemotherapy? Clin. Oncol. (R. Coll. Radiol.)17(3), 138–147 (2005).
   PubMedGoogle Scholar
• Spencer SA, Harris J, Wheeler RH et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck30(3), 281–288 (2008).
   PubMed Web of Science ®Google Scholar
• El-Deiry MW, Futran ND, McDowell JA, Weymuller EA Jr, Yueh B. Influences and predictors of long-term quality of life in head and neck cancer survivors. Arch. Otolaryngol. Head Neck Surg.135(4), 380–384 (2009).
   PubMedGoogle Scholar
• Terrell JE, Ronis DL, Fowler KE et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch. Otolaryngol. Head Neck Surg.130(4), 401–408 (2004).
   PubMedGoogle Scholar
• Rogers SN, Thomson R, O’Toole P, Lowe D. Patients experience with long-term percutaneous endoscopic gastrostomy feeding following primary surgery for oral and oropharyngeal cancer. Oral Oncol.43(5), 499–507 (2007).
   PubMedGoogle Scholar
• Gurney TA, Eisele DW, Orloff LA, Wang SJ. Predictors of quality of life after treatment for oral cavity and oropharyngeal carcinoma. Otolaryngol. Head Neck Surg.139(2), 262–267 (2008).
   PubMedGoogle Scholar
• Owen R, Silver C, Ravikumar T, Brook A, Bello J, Breining D. Techniques for radiofrequency ablation of head and neck tumors. Arch. Otolaryngol. Head Neck Surg.130(1), 52–56 (2004).
   PubMedGoogle Scholar
• Brook A, Gold M, Miller T et al. CT-guided radiofrequency ablation in the palliative treatment of recurrent advanced head and neck malignancies. J. Vasc. Interv. Radiol.19, 725–735 (2008).
   PubMed Web of Science ®Google Scholar
• D’Cruz A, Robinson M, Biel M. mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients. Head Neck26(3), 232–240 (2004).
   PubMedGoogle Scholar
• Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA291(20), 2441–2447 (2004).
   PubMed Web of Science ®Google Scholar
• Yung KC, Piccirillo JF. The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer. Arch. Otolaryngol. Head Neck Surg134(10), 1045–1049 (2008).
   PubMed Web of Science ®Google Scholar
• Kelly C, Paleri V, Downs C. Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer. Otolaryngol. Head Neck Surg136, 108–111 (2007).
   PubMed Web of Science ®Google Scholar
• El-Deiry MW, Futran ND, McDowell JA, Weymuller EA Jr, Yueh B. Influences and predictors of long-term quality of life in head and neck cancer survivors. Arch. Otolaryngol. Head Neck Surg135(4), 380–384 (2009).
   PubMedGoogle Scholar
• Goldstein N, Genden E, Morrison R. Palliative care for patients with head and neck cancer. ‘I would like a quick return to a normal lifestyle’. JAMA299, 1818–1825 (2008).
   PubMedGoogle Scholar
• Tschiesner U, Rogers S, Dietz A, Yueh B, Cieza A. Development of ICF core sets for head and neck cancer. Head Neck32(2), 210–220 (2010).
   PubMed Web of Science ®Google Scholar